SQI Diagnostics' Q3 Loss Jumps 50 Percent | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Canadian microarray-based diagnostics development firm SQI Diagnostics today reported that its net loss for its fiscal third quarter increased 50 percent year over year.

For the three months ended June 30, the Toronto-based company's loss was C$2.7 million (US$2.8 million), or C$.08 per share, compared to C$1.8 million, or C$.06 per share, a year ago.

The firm did not disclose any revenues for the quarter.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: variant linked to obesity risk in Samoans, health of cloned animals, and more.

Researchers explore using genome editing to treat inherited eye diseases, New Scientist reports.

Olympic athletes this summer will also undergo gene doping testing, according to Wired.

A study finds that the lower funding rate seen among women of color is more due to race than gender, according to BuzzFeed News.